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        Chronic kidney disease (CKD) refers to kidney disease that results 
in structural or functional damage to the kidneys due to a variety of 
causes, resulting in irreversible loss of nephron and renal function. The 
incidence and mortality rate of CKD is increasing worldwide, due to the 
II
absence of treatment methods and the existence of various causes of 
disease. Renal fibrosis is a chronic and progressive kidney disorder that is 
associated with many kidney diseases. Recovery from acute kidney injury 
involves the regeneration of the tissue, in which the damaged tissue is 
replaced by new cells of the same lineage. Abnormal or incomplete 
recovery lead to renal fibrosis, which is a cause of chronic, progressive 
renal failure. Considerable research has focused on the development of 
efficient and specific methods to treat renal diseases. Gene therapy using 
gene carriers has the advantages of high transfer efficiency, low toxicity, 
and application to various diseases. In addition, non-viral gene carriers 
also have potential for gene therapy, due to their ease of modification and 
biocompatibility. This study was demonstrated that the protective effects of 
kidney – specific chitonic acid-conjugated polysorbitol gene transporter 
(CBA-PSGT) carrying the gene for hepatocyte growth factor (HGF) as an 
anti fibrotic factor, against renal fibrosis progression. 
      First, CBA, a kidney specific ligand, was synthesized, and conjugated 
it to a PSGT carrier. CBA can effectively target vimentin to the kidney. 
Vimentin is an intermediate filament protein that is found in vascular 
endothelial cells, vascular smooth muscle cells and fibroblasts. Therefore, 
vimentin, which is expressed on the surface of kidney cells or kidney 
tissues, can be used as a target for gene delivery. Moreover, vimentin is 
expressed in the renal interstitial region, as well as in normal and 
abnormal renal tissues. In particular, vimentin can be considered as a 
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marker of renal tubular disorder, owing to its high expression in those 
disorders, including renal atrophy, inflammation, and fibrosis. The 
kidney-specific gene transporter CBA-PSGT as a gene carrier was 
synthesized and evaluated. CBA-PSGT was confirmed a successful gene 
transporter with high stability, due to DNA complexation, minimal toxicity, 
and high gene expression efficiency with the gene. In addition, CBA-PSGT 
was effectively protected from digestion by DNase. 
      Second, unilateral ureteral obstruction (UUO) animal models were 
constructed for the evaluation of the protective effects of CBA-PSGT/HGF 
against renal fibrosis. In the UUO model, the expression of HGF was 
increased by treatment with CBA-PSGT/HGF. The UUO model causes 
renal tissue damage, mainly resulting in atrophy of the interstitial tissue of 
the tubule and fibrosis. In addition, infiltration of inflammatory cells into 
the tubulointerstitial tissue causes inflammatory cytokine release in the 
UUO model. The CBA-PSGT/HGF delivery group was detected less 
damage to the kidney tissue by histological analysis. BUN and creatinine 
levels were used as kidney damage markers, and the expression levels of 
inflammatory cytokines, interleukin-6 (IL-6) and IL-1β were deceased in 
the group that treated of CBA-PSGT/HGF. Renal fibrosis lead to the 
formation and accumulation of collagen in the renal tissues. Therefore, 
collagen formation and accumulation were reduced by gene therapy by 
histological analysis and assessment of the levels of collagen. In addition, 
the expression level of collagen-related proteins, such as ICAM-1, 
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TIMP-1 and α-SMA, which highly expressed in the setting of renal 
injury, as well as metalloproteinase (MMPs), which are enzymes that 
inhibits the formation of extraellular matrix (ECM), were decreased in the 
CBA-PSGT/HGF complex group. 
     In summary, a CBA-conjugated gene transporter was successfully 
synthesized as kidney specific ligand, which targets the vimentin that is 
highly expressed in the setting of renal disease and damage. It is 
characterized that the kidney-specific gene transporter. CBA-PSGT was 
stable due to DNA complexation and it was protected from degradation by 
DNase; the construct also had low toxicity and high delivery efficiency. In 
addition, The study was demonstrated that CBA-PSGT carrying HGF, an 
anti-fibrotic factor, protected against the progression of renal fibrosis in a 
UUO model. CBA-PSGT should be further investigated, to explore its 
potential to alleviate UUO and kidney-related disease using high affinity 
kidney targeting. 
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INTRODUCTION
1. Gene delivery system
     Gene and drug delivery systems, which use a variety of facilitate the 
uptake of genes that have been selected to target the cells or tissues, 
have great therapeutic potentials for various diseases (Kim et al., 2011; 
Langer et al., 1998). Optimization of a gene delivery system requires 
complete understanding of the interactions between the target cells or 
tissues and delivery system. Cell-targeting gene delivery, the most o a 
specific compartment or tissue, which is the most commonly used 
mechanism in endocytosis gene therapy, particularly in cellular uptake of 
non-vial gene delivery system (Langer et al., 2007). Gene therapy, 
defined as a procedure used to treat a disorder or improve the health of a 
patient by genetically modifying the patient`s cells (Stachan et al.,1990), is 
considered an alternative for enzyme or protein replacement therapy. 
Despite various methods or types of gene therapy, the identification of 
mutant genes are responsible for the cause of the diseases. The 
therapeutic gene is loaded in a vehicle, called the vector. The function of 
the vector is to deliver the therapeutic gene to the target cells or organ. 
The most critical step in successful gene therapy is the selection of the 
vector (Ramamoorth et al.,2015). The optimal vector and delivery system 
depends on the target cell and its characteristics, as well as the required 
duration of expression of the gene of interest and the size of the genetic 
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material to be incorporated in the vector (Somia et al., 2000), which may 
fall into the category of a viral, non-viral, or engineered vector.
1.1. Viral vector gene delivery system
      Viral-based gene delivery systems consist of viruses that are 
modified to be replication-deficient, which can deliver genes to target sites 
to facilitate expression (Liao et al.,2009). The most commonly used viral 
vectors are based on retroviruses (Yee et al., 2001), lentiviruses, herpes 
simplex viruses (HSVs), adenoviruses (Jooss et al., 2003), and 
adeno-associated viruses (AAVs) (Jooss et al., 2003; Oligino et al., 
2000).         
      Retro viral vectors are the most frequently used for gene delivery as 
they can transfect dividing cells by passing through the nuclear pores of 
mitotic cells, unlike other viral vectors, including adenoviral and lentiviral 
vectors (Bushman et al., 2007). In addition, retroviral vectors have the 
ability to integrate linearly into the host cell genome, which is useful for 
ex vivo delivery therapy (Fischer et al., 2005). They have been applied 
for familial hyperlipidemia gene therapy and tumor vaccination. However, 
retroviral vectors have limitations, including low efficiency in vivo, 
immunogenicity, the inability to transduce non-dividing cells, and the risk 
of off-target insertion. Thus, they can cause oncogene activation or 
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tumor-suppressor gene inactivation (Fischer et al., 2005).
     Lentiviruses, a subclass of retroviruses, have recently been used as 
gene delivery vectors because of their ability to naturally integrate with 
non-dividing cells, unlike other retroviruses. Lentiviruses can deliver 8 kb 
of sequence; they have been extensively used for ex vivo gene transfer to 
the central nervous system, with fewer instances of immune responses and 
unwanted side effects. The advantages of lentiviral gene delivery systems 
are high efficiency of infection; long-term, stable expression of a 
transgene; low immunogenicity; and their ability to accommodate larger 
transgenes (Federici et al., 2009). 
     HSV vectors are among the most recent viral candidates for gene 
delivery. They can deliver up to 150 kb of transgenic DNA and, due to 
their neurotropic features, they have potential for gene delivery to the 
nervous system (Liu et al., 2008), as well as to cancer cells (Goss et al., 
2002; Goins et al., 2009).
      Adenoviral vectors have been isolated from more than 100 different 
species. Adenovirus serotypes are commonly used in gene therapy, 
particular types 2 and 5. Adenoviral vectors can be utilized for transfer 
into both dividing and non-dividing cells; due to their low host specificity, 
they can be used for gene delivery into a large range of tissues (Thrasher 
et al., 2006). Adenoviral vectors can deliver large-scale DNA particles, up 
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to 38 kb; larger particles do not integrate into the host genome, so the 
resulting gene expression is brief. Although the risk of serious disease 
following clinical application is minimal, gene therapy using adenoviral 
vectors has caused severe side effects and even death (Reid et al., 2002; 
Raper et al., 2003). 
     The advantage of using viral vectors is their natural ability to enter 
cells and express their own proteins. Viral characteristics allow for high 
titer production, high expression levels, and the ability to infect both 
actively dividing and quiescent cell types (Phillips et al., 2005; Worgall et 
al., 2005). Viruses have a high capacity for the physical condensation of 
DNA within the viral capsid (Ledley et al., 1996). IIn addition, the carrier 
system features a viral capsid that protects it from enzymatic degradation. 
This highly evolved and specialized capacity for DNA condensation ensures 
efficient gene delivery from the cell surface to the nucleus, and 
subsequent expression of the encoded protein. DNA condensation enhances 
binding to the cell surface, penetration into the cell, escape from 
intracellular compartments, and transport of the DNA into the nucleus. 
Therefore, viral gene delivery systems are considered the most efficient 
methods of DNA delivery (Mansouri et al., 2004). However, the use of 
these system in gene therapy could be limited by various factors. First, 
there are safety issues with using viral vectors, such as toxicity, immune 
activation, and inflammatory responses (Yee et al., 2001). Second, random 
insertion of DNA into host cell chromosomes may lead to insertional 
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oncogenesis or mutagenesis. In addition, recombination with other viruses 
can produce new, competent viruses (Mansouri et al., 2004). Third, the 
use of viral vectors for gene therapy is limited by the fact that only small 
sequences of DNA can be inserted in the viral genome; thus, large-scale 
alterations may be difficult to achieve. Finally, viral gene delivery systems 
are typically restricted to targeting specific cell types and are associated 
with high production costs (Luo et al., 2000). The limitations of viral 
vectors, especially the safety concerns, have led to the evaluation of 
alternative approaches and the development of non-viral systems. 
1.2. Non-viral vector gene delivery system
     Non-viral vector gene delivery systems have been developed as an 
alternative to viral-based systems. They are classified into physical and 
chemical methods, and they include delivery by gene gun, electroporation, 
particle bombardment, ultrasound utilization, magnetofection, or cationic 
liposomes and polymers. Although these systems have lower gene 
transduction efficiencies than viral systems, they are superior in terms of 
cost effectiveness, availability, and, most importantly, lower rates of 
immune activation. In addition, these systems have no limitations with 
regard to the size of the transgenic DNA constructs, unlike viral delivery 
systems (Nayerossadat et al., 2012). 
     Physical methods of non-viral gene delivery have been applied for in 
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vitro and in vivo gene delivery. They are based on transiently penetrating 
the cell membrane by mechanical, electrical, ultrasonic, hydrodynamic, or 
laser-based means, in order to facilitate the targeting of cells or tissues. 
Naked DNA is susceptible to degradation by DNase and cannot efficiently 
overcome the cellular barriers for delivery to the cell nucleus, due to its 
large size and negative surface charge. Naked DNA alone is able to 
directly deliver a gene (219 kb) to the skin, thymus, cardiac muscle, or 
skeletal muscle, following intravenous, mucosal, or intramuscular 
administration (Blomberg et al., 2002; Bragonzi et al., 1999). Although 
injection of naked DNA is safe and simple, it has low gene delivery 
efficiency and is only appropriate for some applications, such as DNA 
vaccination. 
     The use of a gene gun for DNA particle bombardment is an ideal 
alternative to the injection of naked DNA. Gold and tungsten coated with 
plasmid DNA are typically used for gene delivery. This strategy is a 
modification of a technique that was developed for generating transgenic 
plants, but it is now used in animals, both in vitro and in vivo, as well 
(Knapp et al., 2004; Herweijer et al., 2003). 
     Electroporation is used to enhance cell membrane permeability by 
applying an electrical field. Cell membrane breakdown leads to pore 
formation, which allows the transgene to pass into the cell. This method 
has been used in vivo for many type of tissues, including skin, muscle, and 
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lung (Dean et al., 2003), as well as for tumor treatment (Heller et al., 
2005). On the other hand, the high voltage applied to the tissue can 
damage the organ and affect genomic DNA stability (Young et al., 2005; 
McMahon et al., 2004).  Ultrasound utilization has also been used to 
enhance cell membrane permeability for the delivery of DNA particles, in a 
safe, highly flexible manner. However, the greatest limitation of the system 
is its low efficiency, particularly in vivo.
     Chemical systems are more commonly used than physical systems; 
they typically involve nanomeric complexes, including cationic liposomes 
(micelles) or cationic polymers. These systems are the 2 major types of 
non-viral gene delivery vectors currently under investigation. Both cationic 
liposomes (micelles) and cationic polymers interact electrostatically with 
negatively charged DNA to form complexes, called lipoplexes or 
polyplexes, respectively. The most important advantages of these 
non-viral systems are their ease of use and reliability. In addition, they 
have good bio-safety with low immunotoxicity, and offer diversity in 
modification. Although these 2 non-viral delivery systems have several 
advantages over viral vectors, their success has been limited (Goss et al., 
2002). They have relatively low transfection efficiencies, in comparison 
with viral gene delivery systems. 
     A number of barriers must be overcome in order to increase the 
effectiveness of non-viral vectors. Transfer across the plasma membrane 
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is the most critical barrier to effective DNA transfection. In order for 
naked nucleic acids to cross the cell membrane, a physical method or 
carrier must be used to facilitate cellular uptake, which includes 4 steps 
(Al-Dosari et al., 2009): (1) nonspecific interaction between cationic 
particles and the cell surface, (2) endocytosis into intracellular vesicles 
(endosomes), (3) compaction and release of the DNA particle from the 
endosome, and (4) translocation of the DNA particle into the nucleus, via 
membrane receptors, and transgenic expression (Mair et al., 2009). When 
lipoplex or polyplex particles associate with the cell surface, they enter 
the cell by endocytosis. Many studies have reported receptor-mediated 
delivery via interactions between carbohydrates and cell surface lectins, 
including interactions between galactose and glycoprotein receptors in 
hepatocytes (Hashida et al., 1998; Nie et al.,  2011; Wang et al.,  2008; 
Oh et al., 2016). 
     Cationic lipids have been used for the delivery of encapsulated drugs, 
as well as the delivery of vectors for gene therapy (Shi et al., 2002). 
Interactions between anionic nucleic acids and the surfaces of cationic 
liposomes result in the formation of multilamellar structures. Cationic 
liposomes have several advantageous characteristics, including the 
capability to incorporate hydrophilic and hydrophobic drugs, low toxicity, 
and targeted delivery of bioactive compounds to the site of action (Hofland 
et al., 2002; Mastrobattista et al., 2002). However, they also have several 
disadvantages, that the reticuloendothelial system and the inability to 
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achieve sustained drug delivery over a prolonged period of time, owing to 
their rapid degradation. To overcome these drawbacks, the systems 
magnificate the surface of liposomes with hydrophilic polymers, for 
example, polyethylene glycol (PEG) (Son et al., 2000), integration of the 
pre-encapsulated drug-loaded liposomes within depot polymer-based 
systems (Thomsen et al., 2015). 
       Like cationic lipids, cationic polymers, such as poly-L-lysine 
(PLL), polyethylenimine (PEI), and polyamidoamine dendrimers, interact 
with the negatively charged DNA phosphate groups. These carriers are 
generally accepted due to their ability to efficiently condense DNA and 
interact with cells; they are more stable than the systems that use cationic 
lipids. These carriers form complexes with DNA, which protect it against 
nuclease-mediated degradation (Rasouloanboroujeni et al., 2017). 
       PLL was the first cationic lipid, followed by PEI. PLL is still the 
most widely investigated cationic polymer. However, PEI is the most 
important cationic polymer; it is one of the most positively charged, dense 
polymers. PEI has high transfection activity in vitro and moderate activity 
in vivo. Its linear forms have lower toxicity and higher efficiency than its 
branched forms (McKenzie et al., 1999). Given that PEI has the greatest 
number of primary, secondary, and tertiary amino groups, it also has a 
strong buffering capacity at almost any pH. In constant, Some limitations of 
PEI have application in vivo delivery. However, there are a number of 
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some advantages and disadvantages. The notable factors affecting its in 
vivo application are toxicity and transfection efficiency. 
1.3. Chitosan conjugated gene delivery system
     Among non-viral vectors, chitosan is considered a good gene delivery 
candidate. It is known as a biocompatible, biodegradable system with low 
toxicity and high cationic potential (Safari et al., 2012).  Chitosan, which 
belongs to a family of linear binary polysaccharides, is comprised of β
(1-4) linked 2-amimo-2-deoxy-b-D-glucose (GlcN; D-unit) and 
N-acetylated analogue (GlcNAc;A-unit). It provides a biocompatible 
alternative to cationic polymers, and is widely used as a promising 
non-viral gene delivery system (Akbuga et al., 2016; Thanou et al., 
2002). Nucleic acids can be complexed with chitosan by simple 
complexation or entrapped in chitosan nanoparticles via ionic gelation. 
Chitosan-conjugated DNA nanoparticles have the disadvantages of low 
aqueous solubility and low transfection efficiency (Mansouri et al., 2004; 
Thanou et al., 2002; Corsi et al.,  2003; Mansouri et al., 2004). However, 
recently, several chitosan derivatives have been developed to enhance 
transfection efficiency and solubility at neutral pH. Chitosan-conjugated 
gene carriers have also been modified for high transfection efficiency, and 
can be successfully administered by parenteral, oral, intranasal, pulmonary, 
and dermal routes (Akbuga et al., 2016).
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       Previous studies were demonstrated that vimentin can be targeted 
with high affinity by CBA, prepared by dimerization of 
N-acetylglucosamine (GlcNAc), when conjugated with cationic polymers; 
we found that CBA-conjugated polymers showed higher transfection 
efficiency in vimetin-expression cells (the human embryonic kidney 293T 
cells and epithelial HeLa cells) than their unconjugated counterparts (Kim 
et al., 2011; Singh 2014). Mechanistically, Kim et al., also showed the 
proof-of-concept that these CBAconjugated polymers had no effect when 
surface expression of vimentin was knocked down by RNA interference 
(Kim et al., 2011). This remarkable targeting affinity of CBA for vimentin 
motivated us to combine CBA with recently developed gene transpoter 
(PSGT); PSGT has shown remarkable efficacy for the delivery a variety of 
genetic materials, such as DNA (Kim et al., 2014; Luu et al., 2012; 
Nguyen et al., 2014; Islam et al., 2011), siRNA (Islam et al., 2012; Islam 
et al., 2014A; Islam 2014B; Cho et al., 2015) and microRNA (Muthiah et 
al., 2014; Muthiah et al., 2015), and exhibited remarkable potential for the 




2.1. Kidney injury animal model
      Chronic kidney disease (CKD), a leading cause of kidney failure, is 
still a major health problem, which causes millions of deaths worldwide. In 
the United States alone, 1 in 3 adults are at high risk of kidney diseases, 
and 82,000 people die from kidney failure each year. The current 
treatments have poor efficacy in preventing the progression of the disease; 
in addition, there is no treatment to permanently reverse the damage of 
kidney failure, except kidney transplantation, which is expensive and reliant 
on donor matching and availability (Grande et al., 2015). Recently, 
considerable researches have been conducted recently to find out the key 
regulators (such as HIPK2 (Jin et al., 2012), epithelial to mesenchymal 
transition (Lovisa et al., 2015), defective fatty acid oxidation in renal 
epithelial cells (Kang et al., 2015), mitochondrial abnormality (Zhang et al., 
2015), fibroblast and myofibroblast (Palumbo-Zerr et al., 2015; Strutz et 
al., 2006)) as well as identify the underlying mechanisms causing CKD 
leading to kidney failure; it must be a priority to develop a clinically 
relevant treatment strategy to prevent kidney disease, one of the most 
devastating human health problems. 
      To investigate the mechanisms of disease and effects of 
interventions, a variety of animal kidney disease models have been 
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developed, including spontaneous, genetic, and induced models. The animal 
kidney disease models provide a fundamental understanding of kidney 
biology, physiology, and pathophysiology, and aid in the development of 
therapies. Among the models, the animal CKD model provides the 
opportunity to investigate kidney disease-specific mechanisms and 
molecular pathogenesis, as well as assess potential therapies (Lim et al., 
2014). However, many of these models do not accurately reflect human 
disease.
      Various kidney injury models have been developed, in different 
species and to model specific diseases. An optimal experimental study 
design must include appropriate choices of model, time course, and 
readouts (Lim et al., 2014). Ischemia commonly causes acute kidney injury 
(AKI) in the human population, which is associated with an increased risk 
of developing subsequent CKD (Bellomo et al., 2012; Bucaloiu et al., 
2012). 
      Diabetes nephropathy (DN) models, which address the single largest 
cause of CKD, can be artificially induced, spontaneous, or genetically 
engineered (Lim et al., 2014; Becker et al., 2012). Type I diabetes has 
been most commonly modelled by injection of streptozotocin (STZ). 
Animals in STZ-induced models develop a modest degree of proteinuria 
and kidney toxicity, as indicated by elevated serum levels of creatinine and 
BUN. Patients with type II diabetes often have DN. Type II diabetes is 
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commonly modelled by single-gene mutations of the leptin receptor, as in 
the db/db mouse (Soler et al.,  2012). These models are characterized by 
obesity, hyperglycemia, hyperinsulinemia, and mild to moderate 
hypertension. These abnormalities precede the development of albuminuria 
and glomerular injury (Stevenson et al., 1999).
       The rodent unilateral ureteral obstruction (UUO) model generates 
progressive renal fibrosis. Although complete ureteral obstruction is not a 
common cause of human renal diseases, this animal model for renal 
fibrosis aids in building an understanding of the disorder under 
investigation. The UUO model is useful to examine the mechanisms driving 
tubulointerstitial fibrosis in vivo (Chevalier et al., 2009; Lim et al., 2014; 
Yang et al., 2010). In the UUO model, the obstruction is created surgically, 
and can be experimentally manipulated with respect to timing, severity, and 
duration; reversal of the obstruction permits the study of recovery. Renal 
fibrosis is regarded as the final common pathway for most forms of 
progressive renal disease, as most renal diseases lead to renal fibrosis 
(Yang et al., 2010). Since then, the UUO model has been refined to 
elucidate the pathogenesis of obstructive nephropathy, as well as the 
mechanisms responsible for progressive renal fibrosis (Sharma et al., 
1993).  Within 24 hours, animals in the UUO model experience reduced 
renal blood flow and a lower rate of glomerular filtration. Accordingly, 
hydronephrosis, interstitial inflammatory infiltration, and tubular cell death, 
attributable to apoptosis and necrosis, follow within several days. 
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Progressive fibrosis and tubular cell death appear to be closely associated 
(Docherty et al., 2006). Therefore, these are useful in the study of the 
pathogenesis of renal fibrosis. Lesions, which develop more slowly, may be 
better suited to the study of therapeutic interventions (Chen et al., 2007; 
Windt et al., 2006).
     The surgical procedure for inducing UUO is relatively straightforward. 
Ligation of the ureter is the most frequently used technique. A piece of 
Silastic tubing can be folded perpendicularly across the ureter to create an 
obstruction, or the tubing can be slit and fitted around the ureter 
longitudinally to form a sleeve that creates a partial obstruction (Chevalier 
et al., 2009). The obstructed kidney reaches end stage in approximately 
10-14 weeks (Chevaliar et al., 2009; Chevaliar et al., 2006). 
2.2. Mechanism of kidney fibrosis
     Renal fibrosis is considered a final, common outcome when the kidney 
faces chronic, sustained injury. In response to injurious stimuli, affected 
tissues initially undergo a cascade of events in an attempt to repair, heal, 
and recover from the damage. Renal fibrosis can be quantitated by 
histological analysis of renal collagen distribution in tissue sections stained 
for type I, III, and IV collagen fibrils (Wada et al., 2002). One study found 
that expression of urinary-specific matrix metalloproteinases (MMPs) 
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correlated with the deposition of collagen type I and III in a renal fibrosis 
model (Papasotiriou et al., 2015). Several major pathways are associated 
with the development of renal interstitial fibrosis following UUO in rats, 
including interstitial infiltration by macrophages (Xie et al., 2004), tubular 
cell death by apoptosis, and interstitial fibrosis (Wu et al., 2010). 
Classically activated macrophages can generate tumor necrosis factor-α 
(TNF-α), which regulates pro-apoptotic signaling and renal tubular cell 
apoptosis following UUO (Yeh et al., 2011). Wound-healing processes are 
also activated, including the production and secretion of chemokines and 
cytokines, recruitment of inflammatory cells to the injured sites, activation 
of fibroblasts to produce extracellular matrix (ECM), and the regeneration 
of damaged tissue through cell proliferation and differentiation. However, 
upon exposure to chronic injury, the tissue overproduces ECM, ultimately 
causing fibrotic lesions and tissue scarring (Klahr et al., 2002; Genovese 
et al., 2014). Numerous factors are known to regulate the fibrogenic 
process after tissue injury, including pro-fibrotic (transforming growth 
factor-β or TGF-β, HIF, plasminogen activator inhibitor-1 or PAI-1, 
platelet-derived growth factor, vascular endothelial growth factor or 
VEGF) and anti-fibrotic (hepatocyte growth factor or HGF, and bone 
morphogenetic protein 7 or BMP7) factors (Kellenberger et al., 2015; 
Ognoon et al., 2013; Wong et al., 2014; Persson et al., 2017). These 
factors have a variety of functions depending on the duration and type of 
injury (Kellenberger et al., 2015). 
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     A reduction in renal oxygenation occurs in CKD, along with a 
combination of pathophysiological and morphologic changes that correlate 
with CKD [117]. A reduction in renal oxygenation in CKD induces the 
oxygen-sensitive HIF-1, which is primarily expressed in the tubular 
segments, peritubular endothelial cells, fibroblasts, and glomerular cells 
(Persson et al., 2017). Reduction renal oxygenation in CKD is the 
induction of the oxygen-sensitive HIF-1 , is primarily expressed in the 
tubular segments, in peritubular endothelial cell and fibroblasts as well as 
in glomerular cells (Persson et al., 2017; Haase et al., 2006). HIF 
activation during hypoxia may contribute to renal fibrosis by direct 
transcriptional regulation of target genes that control ECM turnover, and by 
interaction with the pro-fibrotic factor TGF-β1 (Haase et al.,  2006; 
Higgins et al., 2008).
     Hepatocyte growth factor (HGF) promotes hepatocyte proliferation 
and liver regeneration (Lin et al., 2002; Liu et al., 2004). Several reports 
demonstrate that HGF regulates such diverse cellular processes as cell 
survival, proliferation, migration, and differentiation, via binding to the 
c-mesenchymal epithelial transition factor (c-met) receptor(Higgins et al., 
2006; Imamura et al., 2017). HGF binding triggers the activation of the 
c-met receptor through tyrosine autophosphorylation. The kidney 
abundantly expresses HGF and its receptor (Higgins et al., 2008). 
Furthermore, HGF is a potent anti-fibrotic factor that prevents progression 
of chronic renal fibrosis by inhibiting TGF-β activation and 
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epithelialmesenchymal transition (Kellenberger et al., 2015; Mizno et al., 
2008). 
     Some studies have demonstrated that administration of exogenous 
HGF attenuates renal interstitial fibrosis in animal models of obstructive 
nephropathy induced by UUO (Gao et al., 2002; Yang et al., 2002A). 
Administration of HGF not only inhibits the onset and progression of CKD 
but also exhibits therapeutic efficacy even when tissue injury is already 
established. HGF has emerged as an intrinsic factor that prevents kidney 
tissues from the development of fibrotic lesions after chronic injury [123]. 
The reciprocal balance of TGF- and HGF plays a critical role in 
determining if the injured tissues undergo recovery or fibrogenesis. 
Exogenous or endogenous HGF expression would likely provide an 
effective means for the treatment of a wide range of chronic fibrotic 
disorders (Liu et al.,  2004; Yang et al., 2002A; Matsumoto et al., 2014; 
Sakai et al., 2015). 
     Many types of kidney injury induce inflammation as a protective 
response. Conversely, inflammation promotes progressive renal fibrosis, 
which can occur in renal disease, and kidney inflammation leads to the 
production and release of pro-fibrotic cytokines and growth factors (Meng 
et al., 2014; Guiteras et al., 2016). Macrophages have been implicated in 
glomerular and interstitial fibrosis, which can cause the progression of 
CKD (Meng et al., 2014). In addition, the balance between type 1 and 2 
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macrophages is associated with renal injury and influences CKD 
progression (Guiteras et al., 2016).
2.3. Gene delivery system in kidney disease
     For the past several decades, gene therapy has been considered  one 
of the most promising strategies for the treatment of inherited or acquired 
diseases, and several clinical trials of gene therapy products have  
indicated a promising future for the translation of this field into tangible 
bedside applications. In this context, a targeted gene therapy specific to 
the kidneys could be an ideal strategy to improve the therapeutic efficacy 
of a desired gene, as wall as an approach to identify an effective method 
to treat kidney-related diseases. 
       Applications of gene therapy for the kidney face some unique 
challenges due to the structure-function relationship of the nephron (Van 
der Wouden et al., 2004). The kidney is a well-organized and 
differentiated organ with specialized compartments, consisting of tubules, 
vasculature, glomeruli, and interstitium, all of which represent hurdles for 
the gene delivery system; gene carriers encounter these anatomic barriers 
before reaching their specific transfection sites (Chevaliar et al., 2004). 
The nephron consists of many unique, highly specialized, quiescent 
differentiated cell types. 
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       A vector system must be able to gain access via the ureter, and 
possess the ability to manipulate an organ ex vivo at the time of 
transplantation (Imai et al., 2001; Ojeda et al., 2011; Gong et al., 2003). 
To achieve therapeutic effects in the kidney and reduce side effects, 
including transfection of non-target cells in the kidney, the selection of an 
appropriate delivery vector is critical. New therapeutic techniques in renal 
gene therapy typically use non-viral, viral, and cellular vectors (van der 
Wouden et al., 2004; Imai et al., 2001). 
The selection of the route of administration is important for 
improving transfection efficiency. The different methods of administrations 
allow the targeting of different cell types in the kidney. There are 5 
routes of administration, including (1) renal arterial injection, (2) direct 
parenchymal injection, (3) renal venous injection, (4) retrograde delivery 
via the ureter, and (5) subcapsular injection. 
     In general, viral vectors are more efficient for gene therapy than 
non-viral vector systems. The viral gene vectors used in renal gene 
therapy are typically adenoviral, because adenoviruses can transfect a wide 
range of cells, including dividing and non-dividing cells. However, 
adenoviral transfection is transient, and gene expression must be enhanced 
by prolonged incubation or perfusion of the kidney. Other types of viruses, 
such as adeno-associated viruses (AAV), retroviruses, and lentiviruses, 
are also used for renal gene therapy, and can provide long-term gene 
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expression compared with that induced by adenoviruses. 
     A non-viral vector system that has been applied to renal gene 
therapy is the injection of naked plasmid DNA. Direct injection of naked 
plasmid DNA into the renal parenchyma was not employed in renal tissues. 
In general, transfection of naked plasmid DNA results in a low transfection 
efficiency; thus, several techniques have been attempted to enhance its 
efficiency, including physical and chemical transfection methods. The 
physical methods include electroporation and microbubbles with ultrasound. 
After injection of the plasmid into the renal artery, electroporation of the 
kidney leads to a high efficiency of transfection; in addition, the use of 
microbubbles and ultrasound is an efficient technique for the delivery of 
genes to glomerular cells, endothelial cells, and fibroblast. 
     Although non-viral vector systems using liposomes are generally 
nontoxic and non-immunogenic, they have the limitation of low transfection 
efficiency, Therefore, a technique has been developed to enhance their 
transfection efficiency. Hemagglutinating virus of Japan (HVJ) liposomes 
were developed into glycoproteins used to enhance liposome-mediated 
gene transfer. The liposomes comprise a parainfluenza virus that expresses 
2 glycoproteins on its surface, which cooperate to achieve viruscell fusion. 
HVJ liposomes are more efficient vectors than normal liposomes, but they 
lead to only transient expression, and HVJ liposomes are immunogenic. 
Injection of HVJ liposomes via the ureter or renal vein to target interstitial 
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fibroblasts seems to be the best renal gene therapy (Wu et al., 2005).
      New gene therapy methods are usually developed using reporter 
genes, such as reporter genes (Wu et al., 2005), green fluorescent protein 
(GFP) (Picconi et al., 2014), and vimentin (Deng et al., 2015). They 
kidney has some endogenous ndogenouss some activity and displays high 
autofluorescence. For the quantification of transfection efficiency, luciferase 
would be the optimal reporter gene.
3. Experimental purpose
       In the present study, UUO models were prepared, which a widely 
used animal model to study kidney disease (Cavagliri et al., 2015). This 
study investigated that a strategy to treat the UUO rat model using 
CBA-conjugated, PSGT-mediated delivery of HGF, using kidney-specific 
targeting. HGF as a potential genetic factor was used to ameliorate UUO in 
rats because several previous gene therapy studies showed that HGF 
blocks the progression of chronic obstructive nephropathy (Dai et al., 
2004; Gao et al., 2002; Yang et al., 2002A). CBA-PSGT mediated high 
affinity kidney targeting was observed and led to the expression of HGF 
specifically in the kidneys. As expected, CBA-PSGT dramatically alleviated 
urethral obstruction in the UUO rat model; This study investigated the 




     Branched PEI (molecular weight: 12 and 25kDa) and 3-(4, 
5-dimethyl thioazol-2-yl)-2, 5-diphenyl tetrazolium bromide reagent 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sorbitol 
diacrylate (SDA) (MW, 290.27 Da) was purchased from Monomer-Polymer 
& Dajac Labs (Trevose, PA, USA). Chitobiose was kindly provided by 
Yaizu Suisankagaku Industry Co. Ltd. (Shizuoka, Japan). HGF plasmid was 
cultivated in Escherichia coli and purified with a plasmid DNA purification 
kit (Cosmo Genetech, Seoul, Korea). 
Synthesis and characterization of the PSGT, CBA and 
CBA-PSGT
     As we previously described (Islam et al., 2011; Islam et al., 2012; 
Islam et al., 2014A), the PSGT was synthesized by reaction between SDA 
and PEI (12 kDa) using a Michael addition reaction and characterized by 
1H nuclear magnetic resonance(NMR) (AvanceTM 600, Bruker, Mannheim, 
Germany) and gel permeation chromatography (GPC) to confirm the 
success of the reaction. For GPC measurement, a column coupled with 
multi angle laser light scattering (GPC-MALLS) and a Sodex OHpack 
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SB-803HQ (Phenomenox, Torrance, CA, USA) were used to measure the 
actual MW of the polymer. The column temperature was 25° Cata flow 
rate of 0.5㎖/min and as mobile phase,0.5 M ammonium acetate was used.
      To synthesize chitobionic acid (CBA), first a water and methanol 
mixture (5mL) was used to dissolve chitobiose (0.5g). Then iodine 
(1.425g) dissolved in methanol (20mL) was added drop by drop into 
chitobiose solution and mixed for 1 h at 40℃. The color of the solution 
became dark brown after adding iodine solution to CBA. The solution was 
mixed with 4% (weight percent) potassium-hydroxide solution(in 
methanol) until the color of iodine solution disappeared and stirred for 2h 
at 40℃. After cooling, the sample was recrystallized in ethe r and ether 
was removed carefully to get precipitated sample. The recrystallized 
precipitated sample was then dissolved in distilled water and chitobionic 
acid [(GlcNAc)2-COOH] was obtained by separating the synthesized 
product using an amberlite IR-120 column and repeated this separating 
process 2 to 3 times to obtain more purified product. The purified CBA 
solution was then lyophilized and stored at –70℃ until use later.
      To synthesize CBA-PSGT, CBA was conjugated with PSGT using 
DCC/NHS chemistry as coupling agents where the mole ratios of all 
reactants in the reaction are 1: 2: 2: 5 for CBA: DCC: NHS: PSGT, 
respectively. Methanol was used as the dissolving solvent for all the 
reactants. Briefly, CBA was dissolved in methanol at 2 mM concentration. 
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The DCC and NHS were added separately (each at 4 mM concentration) 
and stirred the reaction at room temperature for overnight (16 h) at inert 
condition. The PSGT (10mM concentration in methanol) was then added 
and kept the reaction at RT (and inert condition) for additional 24 h. The 
sample was then dialyzed (MWCO: 3500 Da) in distilled water at 4℃ for 
24h. Any unwanted precipitation (because of the formation of dicyclohexyl 
urea in the reaction) was removed by centrifugation and supernatant was 
collected, lyophilized and CBA-PSGT was stored at –70℃ until use later. 
To characterize the successful synthesis of CBA and conjugation of CBA 
to PSGT, 1HNMR was performed in D2O and the spectra of PSGT, CBA 
and CBA-PSGT were analyzed.
Characterization of the CBA-PSGT/DNA complexes 
     The ability of the CBA-PSGT to complex DNA was evaluated by gel 
retardation procedure according to various N/P (phosphate groups of 
siRNA/amine groups of the polymer) ratios (from 0 to 10). PGL3 was 
used as a plasmid DNA control. Briefly, the CBA-PSGT/PGL3 (0.1㎍) 
complexes at N/P ratios 0.1, 0.5, 1, 3, 5, and 10 were prepared by 
incubating the complexes for 30 min at RT. The final volume was 12㎕ for 
each sample, including the loading dye mixture (Biosesang, Seoul, Korea). 
The samples were loaded onto an agarose gel (1 %) and run at 100 V 
with Tris/borate/EDTA (TBE) buffer for 40 min. Finally, an ultraviolet 
illumination was used to observe the gel. The protection and release of 
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PGL3 was also investigated by gel electrophoresis assay. Briefly, the 
CBA-PSGT/PGL3 complexes (N/P 10) were prepared by incubating the 
complexes for 30 min at RT and further incubated at 37°C for 30 min in 
DNase I. Then, 4㎕ EDTA was added and further incubated for 30 min at 
RT to inactivate DNase. Finally, 5㎕ of sodium dodecyl sulfate (SDS) (1% 
in distilled water) was added and incubated at RT for additional 2 h. 
Electrophoresis was performed for 1 h on a 1 % agarose gel at 50 V with 
TBE running buffer. To check particle morphology, the CBA-PSGT/PGL3 
complexes (N/P 10) were observed by TEM (LIBRA 120, Carl Zeiss, 
Oberkochen, Germany). Particle size and surface charge of the 
CBA-PSGT/PGL3 complexes were analyzed using a DLS (DLS 8000, 
Otsuka Electronics, Osaka, Japan), as we reported earlier (Islam et al., 
2011; Islam et al., 2012; Islam et al., 2014A).
Cell line and culture conditions
     The human embryonic kidney 293T cells and the human adeno 
carcinomatous type II alveolar epithelial A549 cells were obtained from 
American Type Culture Collection, and maintained in Dulbecco’s Modified 
Egles`s Medium (DMEM) at 37°C in humidified air with 5% CO2, 
supplemented with heat-inactivated fetal bovine serum(10%)(FBS, 
Hyclone, Logan, UT, USA) and 1% penicillin/ streptomycin (complete 
culture medium). Cells were subcultured every 2-3days when 
subconfluent. Unless otherwisestated, cells were plated at 1x105㎖/well in 
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24-well culture plates during experimental procedures and invitro 
treatments were done when the cells are in 80% confluent.
In vitro toxicity and transfection assay
     Evaluation of in vitro toxicity of polyplexes was tested with the MTT 
assay. Briefly, 1x105cells/mL/well in 24-well culture plates were exposed 
to the polyplexes(1 mg pGL3) at various NP ratios (at 2.5, 5, 10 and 20) 
for 72 h in serum-free medium. The metabolically active (living) cells 
were spectrophotometrically measured as reduction of the tetrazolium MTT 
dye to insoluble formazan produced by cellular enzymes, as previously 
described (Islam et al., 2011; Islam et al., 2012; Islam et al., 2014A).
     To evaluate transfection efficiency, cells (10 x 104cells/mL/well 
in24-wells culture plates) were grown to approximately 80% confluence 
before treatment with fresh serum free media containing polyplexes(1mg 
pGL3)at various N/P ratios (at 5,10 and 20) and incubated for 4-6h at 3
7℃ under the standard incubation condition. The cells were incubated for 
an additional 48h by replacing serum free media with fresh serum 
containing media. The luciferase assay was carried out as previously 
described (Islam et al., 2011).
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In vivo transfection and luciferase expression in various organs 
of wild-type mice
     Balb/c mice were obtained from the Human Cancer Consortium, 
National Cancer Institute Breeding Colony (Frederick, MD, USA) and 
maintained in a laboratory animal facility with temperature and relative 
humidity maintained at 23±2°C and 40±100% under a 12 h light/dark 
cycle. Mice (n=3) received PBS, naked pGL3, PSGT/pGL3 and 
CBA-PSGT/pGL3 polyplexes (30㎍ of pGL3/mouse) intravenously via 
tail-vein injection. Mice were sacrificed after 72 h and whole organs 
(lung, heart, liver, spleen and kidney) were collected immediately for 
extraction of total RNA using TRizol solution (Invitrogen, USA). Reverse 
transcription of total RNA to cDNA was performed using AccuPower 
CycleScript RT PreMix (Bioneer, South Korea). Luciferase and GAPDH 
mRNAs were quantified by quantitative real-time PCR (qRT-PCR) 
analysis using TOPreal® qPCR Premix (Enzynomics, South Korea) on 
iCycler Real-Time Detection System (BioRad, USA) using following 
primers; Table 1. Finally, luciferase mRNA expression level was 
normalized with GAPDH mRNA expression.
Preparation of UUO rat model and administration of HGF gene
     Five weeks old male Sprague Dawley (SD) rats were purchased from 
Nara Biotech. Inc. (Seoul, Korea) and kept in a laboratory animal facility 
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with a constant temperature of 23±2℃ and relative humidity of 40±10% 
under a regular 12h light/dark cycle. The rats underwent surgery to induce 
UUO. Briefly, under pentobarbital anesthesia, the left ureter was exposed 
through a lateral incision and ligated with 4-0 silk (Ethicon). After 
surgery; the rats were kept in the laboratory animal facility for 14 days to 
induce UUO. The sham (healthy control) rats were un-operated, thus the 
ureters were not ligated. The rats were randomly divided into the 
following five groups: sham (healthy control rat) and four other UUO 
groups (UUO control, naked HGF, PSGT/HGF and CBA-PSGT/HGF 
complexes). PSGT/HGF and CBA-PSGT/HGF complexes were prepared at 
N/P ratio of 10 as explained earlier (50㎍ HGF gene/rat) and injected 
intravenously at days 3, 7 and 10 after UUO surgery before sacrificing the 
rat on day 14. All the experimental procedures in this study were 
performed using processes approved by the animal care and use committee 
of Seoul National University (SNU-131205-2).
Pathological assays
     The kidney tissues were fixed in 4% paraformaldehyde and embedded 
in paraffin for histological evaluation. Paraffin-embedded renal samples 
were sectioned, prepared at a thickness of 5μm and placed on charged 
glass slides (Fisher Scientific, Fairlawn, NJ, USA). The samples were 
scanned for histopathological examination, Sirius red staining for evaluating 
the accumulation of collagen, and immunohistochemistry. The slides were 
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stained with hematoxylin and eosin (H&E) for histopathological analysis. 
The accumulation of collagen was evaluated via Sirius red staining 
according to manufacturer’s instructions (Sigma, Germany). The degree 
of tubular injury was judged by H&E staining. The tissue injury score was 
estimated based on random observation of three fields per each examined 
kidney and the magnitude of tubular injury was scored into five levels on 
the basic of the percentage of affected tubular in a high-power filed under 
light microscope. The tissue injury score was recorded according to this 
estimation: 0, none; 1, <25%; 2, 23-50%;3, 50-75%, 4> 75% (Imai et al., 
2001). The blood urea nitrogen (BUN) (Arbor Assays) and creatinine 
(Cayman Chemical) levels in serum were measured according to the 
manufacturer instructions.
Western blot analysis
     Kidney tissues were homogenized and protein concentrations were 
measured by a Pierce BCA Protein Assay kit (Thermo, Rockford, IL, 
USA). An equal amount of protein (25㎍) was loaded onto a 
SDS-containing gel and transferred to nitrocellulose membrane using Neon 
transfection kit (Invitrogen, Camarillo, CA, USA). The membranes were 
blocked and incubated with their corresponding primary antibodies at 4oC. 
Immunoblotting was performed with primary antibodies of HGF (Abcam 
Inc., Cambridge, MA, USA), ICAM-1, TIMP-1 (Santa Cruz, CA, USA), and  
α-SMA (AbFrontier, Seoul, Korea). After washing with TTBS, the 
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membranes were incubated with secondary antibody of GAPDH 
(AbFrontier, Seoul, Korea). The bends of interest were obtained with 
Ez-Capture MG image analyzer (ATTO, Tokyo, Japan).
Quantitative analysis of PCR products
     Total RNA was extracted by Quick Gene RNA cultured cell kit 
(Kurabo, Japan) following the manufacturer`s protocol and used for cDNA 
synthesis with a reverse transcription kit by GeNet Bio. The values of 
gene expression were normalized against GAPDH. The sequences of the 
primers that were used for the qPCR were as follows Table 2. 
Statistical analysis
     Quantification of Western blot analyses was performed with the 
Multi-Gauge ver. 2.02 program (Fujifilm, Tokyo, Japan). Quantitative data 
are given as mean ±SD. The results were analyzed by an independent 
samples t-test (GraphPad Software, San Diego, CA, USA). P<0.05 was 
considered as significant, whereas P<0.01 and P<0.001 were considered as 
highly significant, respectively. 
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Characterization of PGST, CBA, and CBA-PSGT 
     Michael-type addition reaction was employed to synthesize PSGT 
prepared from the reaction between SDA and low molecular weight PEI as 
the researchers reported previously (Fig. 1A) (Islam et al., 2014A). A 
transporter for DNA motivated me to apply PSGT for kidney-specific 
therapy by tuning the chemistry of this novel biomaterial with synthesized 
according to the previous report (Kim et al., 2011; Singh et al., 2014) 
(Fig. 1B). Conjugated with PSGT using DCC/NHS chemistry synthesize 
CBA-PSGT gene carrier. 
       In the reaction, the DCC and NHS activated the carboxylic acid 
groups of CBA and promoted their reaction with amine groups of PSGT, 
forming amide linkages to synthesize CBA-PSGT (Fig. 2). The PSGT, 
CBA and CBA-PSGT were found completely water soluble due to their 
hydrophilic property. 1H NMR was performed in D2O to characterize these 
compounds.  The 1H NMR spectrum of CBA-PSGT (after reaction) was 
compared with the individual spectrum of PSGT and CBA (before reaction) 
in order to validate their successful conjugation.
       In this regard, Figure 3, shows that CBA has its major proton peaks 
at ppm value around 2.0, whereas no peaks appeared at this range for 
PSGT (before reaction), however, CBA-PSGT has those clear peaks at 
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that region, comfirming that CBA was successfully conjugated to PSGT and 
it was estimated by 1H NMR that about 2.41 mol-% of CBA was remained 
attached in CBA-PSGT product. 
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Figure 1. Synthesis and physicochemical characterization of CBA-PSGT.
(A) PSGT was synthesized by Michael addition reaction between SDA and 
PEI (12kDa) in DMSO at 80℃. (B) synthesis of chitobionic acid (CBA). 
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Figure 2. Synthesis and physicochemical characterization of CBA-PSGT. 
(C)synthesis of CBA-PSGT. CBA was conjugated with PSGT using 
DCC/NHS chemistry as coupling agents where the mole ratios of all 
reactants in the reaction are 1:2:2:5 for CBA:DCC:NHS:PSGT, respectively. 
Materials and methods section explain the entire synthesis scheme in 
detail. 
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Figure 3. Representative 1H NMR spectra of CBA, PSGT, and CBA-PSGT.
CBA-PSGT is showing a successful conjugated of CBA to PSGT and 
mod-% of CBA in the conjugate.
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CBA-PSGT stably complexes with DNA and protects DNA 
from enzymatic degradation
     I ultimate goal of this work was to prepare a kidney-targeting carrier 
system which can effectively deliver hepatocyte growth factor (HGF) in a 
form of plasmid DNA. Thus, in order to determine the DNA complexation 
ability of CBA-PSGT, gel retardation assay was performed at various N/P 
ratios ranging from 0.1 to 10. PGL3 was used as a model DNA. It was 
found that CBA-PSGT was remarkably effective to condense DNA at N/P 
ratio as low as 0.5 (Fig. 4), suggesting an excellent DNA condensation 
ability by the synthesized targeted polymer. The CBA-PSGT is effective 
in condensation of DNA. To check whether CBA-PSGT can protect the 
complexed DNA from degradative enzymes and facilitate releases, gel 
electrophoresis was performed in the presence or absence of DNase I 
enzyme. Figure. 5 shows that the naked DNA was degraded eventually in 
the presence of DNase. Whereas CBA-PSGT completely protected DNA　
from the enzyme, suggesting that CBA-PSGT is very efficient to protect it 
from enzymatic degradation and facilitate the release of the complexed 
DNA. 
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Figure 4. The stability of DNA complexation of CBA-PSGT Agarose gel 
electrophoresis of CBA-PSGT/DNA complexes at various N/P ratios of 
0.1-10. One microgram of PGL3was used as DNA to complex with 
CBA-PSGT.
Figure 5. CBA-PSGT and DNA complexes gene successfully protect from 
DNA degradation enzyme. Naked PGL3 and CBA-PSGT/PGL3 complexes 
(N/P 10) were incubated with or without DNase I for 30min at 37℃ with 
gentle shaking. Sodium dodecyl sulfate (1%) was used to release the PLG3 
from the complexes. 
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Physicochemical characterizations of CBA-PSGT
     The physicochemical characterizations of the polyplexes are the 
prerequisite factors to determine their efficacy because the therapeutic 
effectivity largely depends on the particle size, surface charge and shapes. 
The particle sizes were ranged from 110.6, 114.9 and 129.3 nm for N/P 
ratios of 2.5, 5 and 10, respectively measured by DLS. (Fig. 6A). The 
surface charge of the polyplexes was near neutral as expected (about 
4-5mV) because of the presence of many hydroxyl groups in CBA-PSGT 
which hindered the surface charge of the particles (Ialam et al., 2011; 
Islam et al., 2012; Islam et al., 2014A). TEM images showed that 
CBA-PSGT/DNA complexes are nanometer-scaled size, uniformly 
distributed and compact in their shape as shown in Figure 6B, which 
supports the DLS analysis.
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Figure 6. Physicochemical characterizations of CBA-PSGT.  (A) Particle 
size were measured at various N/P ratios of 2.5, 5, and 10 (n=3; mean± 
SD). (B) Transmission electron microscopic (TEM) image of 
CBA-PSGT/PLG3 complexes (N/P 10;bar denotes 200nm).
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CBA-PSGT/HGF complexes exhibit minimal toxicity 
     Toxicity is one of the major concerns to develop an effective 
polymeric gene delivery system having negligible side effects. To test in 
vitro toxicity of CBA-PSGT, 293T and A549 cells were investigated by 
incubating them with the polyplexes. PSGT/DNA and PEI 25kDa/DNA 
complexes were also checked and compared with CBA-PSGT/DNA 
complexes. The results from Figure 7 showed that both PSGT and 
CBA-PSGT complexes exhibited similar cell viability percentages at 
various N/P ratios from 2.5 to 20, whereas the toxicity of PEI 25kDa 
polyplexes was increased with the increase of N/P ratio in both the cell 
lines. At N/P ratio of 2.5, cell viabilities of PEI 25 kDa polyplexes were 
about 85 % in both 293T and A549 cells, however cell viability drastically 
dropped to near 40 % and 50 %, respectively in 293T (Fig. 7A) and A549 
cells (Fig. 7B) as the N/P ratio increased to 20. One the other hand, at 
N/P ratios from 2.5 to 10, both PSGT and CBA-PSGT exhibited near or 
over 90 to 95 % of viable cells in both the cell lines. At N/P ratio of 20, 
cell viability reduced slightly, however still maintained near or over 80 % 
cell viability, suggesting that the modification of PSGT with CBA did not 
affect on cytotoxicity of CBA-PSGT polymer.
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Figure 7. Cytotoxicity at various N/P ratios (from 2.5 to 20) of 
CBA-PSGT/PGL3 and PEI 25kDa/PLG3 complexes in (A) 293T (n=3, 
mean± SD) and (B) A549 cells (n=3, mean± SD). 
46
CBA-PSGT/HGF complexes greater transfection efficiency in 
embryonic kidney cells in vitro
     To investigate the differences in transfection activity among 
CBA-PSGT, PSGT and PEI 25kDa, an embryonic kidney carcinoma cell 
line (293T) was used and compared the transfection with A549 cells, 
which is a lung cancer cell line to depict the fact that CBA-PSGT, due to 
have high-specificity, could be able to provide an increase transfection 
activity in kidney cells compared to other types and its unmodified form. 
PGL3 was used as a DNA at various N/P ratios with the polymers and 
luciferase assay was performed to estimate the luciferase relative light 
unites (RUL) per mg of protein. The results in Figure 8A showed that the 
transfection efficiencies of CBA-PSGT at various N/P ratios were 
significantly higher in 293T cells compared with that of unmodified PSGT 
and also better than PEI 25kDa as well as Lipofectamine 2000 used as 
controls. On the other hand, there were no differences in transfection 
efficiencies between PSGT and CBA-PSGT in A549 cells (Fig. 8B); rather 
the transfection of PSGT at N/P ratio of 20 was higher than CBA-PSGT, 
suggesting that CBA-PSGT was no better than PSGT to transfect A549 
cells but highly effective in 293T cells. The differences in transfection 
efficiencies of PSGT and CBA-PSGT between 293T and A549 cells imply 
that CBA-PSGT had a more effective interaction with 293T cells 
presumably because of its targeting CBA moiety with the cells having 
vimentin receptors which A549 cells do not possess, suggesting that 
CBA-PSGT may be useful as kidney targeting gene carrier. 
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Figure 8. Transfection efficiency of CBA-PSGT/PGL3, PSGT/PGL3 and 
PEI 25kDa/PGL3 complexes at various N/P ratio in (A) 293T and (B) 
A549 cell lines.
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In vivo kidney-specific targeting in wild-type mice by 
CBA-PSGT/HGF complexes
     To elucidate better understanding on in vivo kidney targeting ability 
of CBA-PSGT system, mice were intravenously injected with 
CBA-PSGT/PLG3 polyplexes and luciferase mRNA expression was 
evaluated in kidney as well as in various other organs including lung, 
heart, liver, and spleen compared to that of PSGT/PGL3 (Fig. 9). PBS and 
naked PGL3 were injected as negative controls. Luciferase mRNA 
expression in organs were normalized with that of the house–keeping 
GAPDH mRNA expression and it was found that the CBA-PSGT was 
remarkably effective to transfect kidneys since it showed high luciferase 
mRNA expression which was more than two-fold higher in kidneys 
compared to the expression in spleen and about 10-fold higher than that 
in lung, heart, and liver. The negative controls showed minimal luciferase 
expression in all organs. As expected, it was found that the luciferase 
activity of CBA-PSGT polyplexes in kidney was more than 3-fold 
higher(P<0.001) than that of unmodified PSGT polyplexes, rendering that 
CBA-PSGT is highly effective to target kidneys in vivo and holds a 
promising potential to use as therapeutic gene delivery system against 
kidney-related disorder.
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Figure 9. In vivo kidney-specific targeting in wild-type mice by 
CBA-PSGT/HGF complexes in vivo kidney targeting efficacy of 
CBA-PSGT system. 
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Establishment of UUO model for identification of CBA-PSGT 
transporter efficiency 
     To investigate the targeting specificity of CBA-PSGT/HGF complexes 
to renal lesion, the UUO model in rats were developed by operating and 
tieing the left ureter of rats The left ureter was operated via a lateral 
incision and ligated (Fig. 10A). The obstructed kidneys displayed activation 
of fibrosis on day 7 after surgery and caused damage of kidney both 
medulla and cortex tissues. Following surgery to induce UUO, HGF gene 
was delivered (as naked HGF, or as complexed with PSGT or as 
CBA-PSGT) at days 3, 7, and 10 via intravenous injection. HGF gene was 
applied because it is widely used in kidney gene therapy studies for the 
hope to treat chronic renal disease such as kidney fibrosis (van der 
Wouden et al., 2004; Imai et al., 2001; Ojeda et al., 2011). Figure 10B
showed that the right nonobstructed kidney or left obstructed kidney was 
analyzed 14 days after the operation.
51
Figure 10. Establishment of UUO model for identification of CBA-PSGT 
transporter efficiency (A) Operation in kidney and tie of left ureter, (B) 
the kidney after establishing of UUO model.
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Targeted HGF delivery to renal lesion of UUO rat by 
CBA-PSGT/HGF complexes 
     The untreated UUO rat model was used as a negative control. I found 
that the CBA-PSGT/HGF complexes successfully targeted kidneys, 
determined through the expression of HGF gene. The results showed a 
significantly increased expression of HGF in CBA-PSGT/HGF group since 
the DAB signals in CBA-PSGT/HGF was mush higher compared to that in 
control, naked HGF, and PSGT/HGF group in UUO model rats showed in 
immunohistochemistry analysis (Fig 11A). Futhermore, the mRNA level of 
HGF was significantly elevated for CBA-PSGT/HGF complexes compared 
to all other groups (Fig. 11B). The protein level of HGF gene for 
CBA-PSGT/HGF group was highly expressed significantly more than that 
of naked HGF and PSGT/HGF as well as the control group determined by 
Western blot assay (Fig. 11C) and it`s represented quantitative analysis. 
These results clearly represent that the CBA-PSGT/HGF complexes can 
successfully target kidneys to deliver and express therapeutic gene. 
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Figure 11. The efficiency of CBA-PSGT/HGF complexes to target kidneys 
was demonstrated by specific HGF expression in kidney tissues. The 
expression of HGF in UUO model rats were examined and confirmed by 
(A) immunohistochemistry (magnification, x40). Total kidney lysate were 
also used to evaluate the delivery efficacy of CBA-PSGT/HGF complexes 
to the kidneys of UUO model rats. (B) The mRNA levels of 
semi-quantitative RT-PCR analysis. (n=3; mean±SD; *P<0.05 and 
**P<0.01 compared to sham; $$$P<0.001 compared to control, ###P<0.001 
compared to naked HGF; &&&P<0.001 compared to PSGT/HGF).(Continued 
next page)
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(Continued) Figure 11. The efficiency of CBA-PSGT/HGF complexes to 
target kidneys was demonstrated by specific HGF expression in kidney 
tissues. The expression of HGF in UUO model rats were examined and 
confirmed by (C) Western blot assay. GAPDH represents a house-keeping 
control gene expression. (n=3; mean±SD; **P<0.01 compared to sham; 
$P<0.05 compared to control, ###P<0.001 compared to naked HGF; 
&&&P<0.001 compared to PSGT/HGF).
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CBA-PSGT/HGF complexes remarkably reduced renal 
pathogenesis
     To check the prevent effects of CBA-PSGT/HGF complex on the 
progression of renal morphologic lesions and interstitial fibrosis, the UUO 
kidneys were examined histopathological analysis. The untreated, naked 
HGF, and PSGT/HGF- delivered UUO kidneys were used as controls. 
Figure 12 showed that the tubules in both medulla (Fig. 12A) and cortex 
(Fig. 12B) region. The UUO model groups including control, naked HGF, 
and PSGT/HGF developed severe renal lesions at 14 days after UUO, 
which observed numerous urinary casts. In UUO model groups, pathological 
changes in the renal tissue were observed renal tubular epithelium damage 
as well as a urinary cast in medulla region and glomerular enlargement, 
increased mesangial matrix, and nodular glomerulosclerosis in cortex region 
(Wu et al., 2010). On the other hand, CBA-PSGT/HGF reversed these 
morphologic injuries including tubular damage (in both cortex and medulla 
region) and also showed minimal urinary casts similar to the sham control. 
In particular, UUO models groups including control, naked HGF, and 
PSGT/HGF were obviously observed interstitial fibrosis with interstitial 
accumulation of mononuclear leukocytes. In addition, histological evaluation 
showed that the development of nodular glomerulosclerosis in cortical area.
      The results suggest that CBA-PSGT ameliorated the tubular damage 
by targeted delivery of HGF to UUO kidney region. In addition, it also 
identified by a quantitative scoring of tubular injury in H&E staining (Fig. 
12C). The index score of tubular damage on CBA-PSGT/HGF group was 
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significantly reduced similar for sham control group. By contrast, there 
were significantly effects on the induction of the tubular damage score by 
UUO groups including control, naked HGF, and PSGT/HGF. Although the 
UUO model slightly improved the morphologic injury in both cortex and 
medulla region, CBA-PSGT/HGF resulted in a remarkable inhibition of 
morphologic damages seen in this model. 
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Figure 12. The effect of CBA-PSGT/HGF complexes on pathological 
change in kidney tissues (both medulla and cortex) of UUO model (A) A 
medulla and (B)cortex renal morphology in UUO model through H&E 
staining (magnification, 20X). (Continued next-page)
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(Continued) Figure 12. The effect of CBA-PSGT/HGF complexes on 
urinary casts formation and collagen accumulation in kidney tissues of UUO 
model (C) Scale of renal tubular injuries. The significance was analyzed 
using paired t-test (n=3; mean±SD; **P< 0.01 compared to Sham, ##P< 
0.01 compared to control, $P< 0.01 compared to Naked HGF, &P<0.05 
compared to PSGT/HGF). 
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CBA-PSGT/HGF complexes reduce renal injury and 
inflammatory response in UUO rat model 
       To evaluation of renal injury, the renal injury was evaluated by 
measuring the level of blood urea nitrogen (BUN) and creatinine in serum 
of UUO rat model using enzymatic method after treatment with the 
targeted CBA-PSGT/HGF system. The BUN in serum significantly 
increased in UUO models including control, naked HGF, and PSGT/HGF. 
The delivery with CBA-PSGT/HGF complexes provided a greater reduction 
of BUN than other UUO models, but similar sham control group. Likewise,  
CBA-PSGT/HGF complexes was significantly affected by reduction of 
creatinine levels in serum (Fig. 13A and 13B). The inflammatory response 
was further examined by analyzing the expression pro-inflammatory 
cytokiens such as IL-6 and IL-1β, which could be secreted by immune 
response and injured tubule cells (Cui et al., 2013) were significantly 
down-regulated in CBA-PSGT/HGF complexes similar for sham (Fig. 14A
and 14B). These results suggest that the delivery with CBA-PSGT/HGF 
complexes may lead to alleviate renal injury and decrease inflammation 
levels compared to other UUO models. 
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Figure 13. The effects of CBA-PSGT/HGF complexes on renal injury on 
(A) blood urea nitrogen (BUN) and (B) creatinine levels. The significance 
was analyzed using One-Way ANOVA (n=3; mean±SD; **P<0.01 and 
***P<0.01 compared to sham; ##P<0.01 and ###P<0.001 compared to control 
group; $P<0.05 and $$$P<0.001 compared to Naked HGF; &&P<0.01 and 
&&&P<0.001 compared to PSGT/HGF). 
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Figure 14. The effects of CBA-PSGT/HGF complexes on renal 
inflammation with UUO model on (A) IL-6 and (B) IL-1β The 
significance was analyzed using One-Way ANOVA (n=3; mean±SD;  
*P<0.05 and ***P<0.01 compared to sham; #P<0.05, ##P<0.01 and 
###P<0.001 compared to control group; $P<0.05 and $$P<0.01 compared to 
Naked HGF; &P<0.05 compared to PSGT/HGF). 
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CBA-PSGT/HGF complexes remarkably reduced accumulation 
and deposition of collagens
     Collagens are the main components of the extracellular matrix (ECM) 
and strongly associated with the progressive renal fibrosis and injury 
(Chevalier et al., 2009), since the processing of the pathogenesis of renal 
fibrosis starts by excessive accumulation and deposition of ECM. The 
accumulation and deposition of collagen I and II was examined in UUO 
model by qRT-PCR. Figure. 15A and 15B showed collagen type I and II 
mRNA expression in renal tissues, respectively and it was found that the 
high affinity targeting of HGF by CBA-PSGT eliminated collagen 
accumulation specifically and remarkably compared to that of all other 
groups. UUO significantly increased kidney collagen contents, the induction 
of collagen deposition was observed in UUO control, naked HGF and 
PSGT/HGF unlike the targeted CBA-PSGT/HGF group which is similar to 
sham control. CBA-PSGT/HGF inhibited collagen I and II expression, 
resulted in marked suppression in the kidney. Furthermore, to evaluate 
collagen deposition in renal tissues, the Sirius red staining was performed 
in the renal of UUO model indicating by red color. Compared with 
CBA-PSGT/HGF, the UUO model groups including control, naked HGF, and 
PSGT/HGF showed much more collagen deposition and more prominent 
fibrosis (Fig 16A) which was nearly similar to the healthy sham control 
mice and also determined the levels of total renal collagen sections were 
quantified by image analysis software using Image J as shown in Figure. 
16B. 
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Figure 15. The effect of CBA-PSGT/HGF in collagen expression in 
kidneys of UUO model The effect of CBA-PSGT/HGF complexes on (A) 
Type I and (B) II collagen mRNA levels. The significance was analyzed 
using t-test (n=3; mean±SD; **P<0.01 and ***P<0.01 compared to sham; 
###P<0.001 compared to control group; $$$P<0.001 compared to Naked 
HGF;  &&&P<0.001 compared to PSGT/HGF). 
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Figure 16. The effect of CBA-PSGT/HGF complexes on collagen 
accumulation in kidney tissues of UUO model (A) Collagen accumulation 
was confirmed by Sirius red staining (magnification, 20X), and (B) 
quantification of the percentage of collagen accumulation with Sirius red 
staining in medulla by densitometer analysis.  The significance was 
analyzed using paired t-test (n=3; mean±SD; *P< 0.05 and ***P< 0.001 
compared to Sham,  ###P< 0.001 compared to control, $P< 0.01 compared 
to Naked HGF, and &&&P<0.001 compared to PSGT/HGF). 
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CBA-PSGT/HGF complexes remarkably reduced 
collagen-related renal fibrotic factors in UUO model
      To checked expression of collagen-related proteins, the levels of 
ICAM-1 and TIMP-1, collagen-related proteins were confirmed in renal 
tissues of UUO model treated by the experimental groups using 
immunoblotting assay as shown in Figure 17A and 17B, respectively. The 
results showed that both ICAM-1 and TIMP-1 expression were markedly 
down-regulated by HGF delivery using CBA-PSGT, but suppressed in 
UUO control, naked HGF and PSGT/HGF, respectively. The ICMA-1 
expression as also critical factor involved in the recruitment of leukocyte 
to injured renal tissues. As shown in Figure 12 and 14, the inflammatory 
response was enhanced on renal injury tissue in UUO model including 
control, naked HGF, and PSGT/HGF. In addition, although PSGT/HGF had 
an effect to slightly reduce TIMP-1 level, TIMP-1 expression level 
increased in UUO model with control, naked HGF and PSGT/HGF, which 
was not superior compared to that of CBA-PSGT/HGF. These results 
suggests that CBA-PSGT has a high targeting efficacy to delivered HGF 
to renal tissues and down-regulates the fibrotic related factors.
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Figure 17. The effect of CBA-PSGT/HGF in collagen-related protein 
expression in kidneys of UUO model The expression of collagen-related 
proteins; (A)  ICAM-1 (Continued next page)
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(Continued) Figure 17. The effect of CBA-PSGT/HGF in collagen-related 
protein expression in kidneys of UUO model rats.  The expression of 
collagen-related proteins; (B) TIMP-1 in kidney tissues of UUO models 
and sham rats. The significance was analyzed using t-test (n=3; 
mean±SD; **P<0.01 and ***P<0.01 compared to sham; ##P<0.01 and 
###P<0.001 compared to control group; $P<0.05 and $$$P<0.001 compared 
to Naked HGF; &&P<0.01 and &&&P<0.001 compared to PSGT/HGF). 
69
CBA-PSGT/HGF complexes significantly down-regulate       
α-SMA expression in UUO model
      Figure 18, demonstrated that the effects of CBA-PSGT/HGF in 
obstructed kidneys among five different treatment groups by 
immunohistochemistry (IHC), immunofluorescence (IF) assays, mRNA 
level, and protein expression level of α-SMA. α-SMA is well known as 
a key protein that causes progression of renal fibrosis (Zhou et al., 2013). 
The CBA-PSGT/HGF complexes remarkably reduced α-SMA expression 
and retained a similar level to sham control compared to that of UUO 
control, neked HGF and non-targeted PSGT/HGF system by IHC and IF 
assays (Fig. 18A and B, respectively). In addition, the mRNA and protein 
expression of α-SMA were also significantly inhibited by 
CBA-PSGT/HGF compared to that of all other groups (Fig. 18C and 18D), 
futher supports the results of IHC and IF assays. These results strongly 
demonstrate that CBA-PSGT/HGF delivery system could provide a 
potential and effective therapy for renal dysfunction in vivo. The overall 
mechanism of kidney-targeted HGF-delivered CBA-PSGT system to 
prevent renal fibrosis is schematically represented in Figure 19.
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Figure 18. Delivery of HGF by CBA-PSGT/HGF complexes suppresses α
-SMA expression in UUO model (A) Immunohistochemistry of α-SMA 
expression in kidney tissues of CBA-PSGT/HGF complexes delivered rats 
(magnification, 20X). and Quantification of the percentage of α-SMA 
expression with immunohistochemistry by densitometer analysis. 
(Continued next page)
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(Continued) Figure 18. Delivery of HGF by CBA-PSGT/HGF complexes 
suppresses α-SMA expression in UUO model (B) immunofluorescence of 
α-SMA expression (C) Quantification of α-SMA mRNA levels in kidney 
tissues of CBA-PSGT/HGF complexes delivered animal model (Continued 
next page)
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(Continued) Figure 18. Delivery of HGF by CBA-PSGT/HGF complexes 
suppresses α-SMA expression in UUO model (D) Western blot of       
α-SMA expression (GAPDH represents a house-keeping control gene 
expression). The significance was analyzed using One-Way ANOVA (n=3; 
mean±SD; *P<0.05, **P<0.01 and ***P<0.001 compared to sham; ##P<0.01 
compared to control; $P<0.05 and $$P<0.01 compared to naked HGF; 
&P<0.05 and &&&P<0.001 compared to PSGT/HGF).
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Figure 19. A schematic representation on the overall mechanism of 
kidney-targeted HGF-delivered CBA-PSGT system to prevent renal 
fibrosis in UUO model (A) The schematic illustration on the successful 
synthesis of CBA-PSGT and stable complexation of CBA-PSGT with HGF 
gene. (B) The mechanism of CBA-PSGT/HGF to deliver HGF and prevent 
renal fibrosis in UUO model rats.
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DISCUSSION
       In light of targeted gene therapy to alleviate kidney dysfunction, 
CBA-PSGT/HGF complexes exhibited remarkable efficacy. Renal fibrosis is 
considered as the final common progressive renal diseases, and involves 
glomerular sclerosis or interstitial fibrosis. Studies have been conducted to 
develop kidney target gene transporter to treat CKD. This study clearly 
demonstrate that delivery of HGF gene with CBA-PSGT protects renal 
fibrosis, following to (1) mechanism of kidney specific targeting gene 
transporter, (2) UUO model with features of renal fibrosis, and (3) 
mechanism of protect of renal fibrosis.
       (1) Mechanism of kidney specific targeting gene transporter : Gene 
transporters should be suited precisely on stability of DNA condensation, 
protection from degradation enzyme, low toxicity, and high efficiency with 
gene targeting to targeted region. CBA-PSGT was demonstrated excellent 
DNA condensation and protection from enzyme-mediated degradation 
together with suitable physicochemical properties (Fig. 4 and 5) and 
minimal toxicity which favored them to apply as a carrier for HGF to 
specifically target and treat kidney dysfunction (Nakamura et al., 2010). 
Moreover, CBA-PSGT showed the highest kidney specific-delivery 
efficiency at both in vitro and in vivo.  
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       Previous study demonstrated that vimentin and desmin show 
GlcNAc-binding lectin-like activity on the surface of cells and possess 
strong avidity to GlcNAc ligands (Kobayashi et al., 2009; Ise et al., 2010). 
GlcNAc-conjugated agent can be targeted to vimentin- and 
desmin-expressing cells and tissues (Kobayashi et al., 2010). Vimentin is 
a type III intermediate filament protein found in cells of mesenchymal 
origin, vascular endothelial cells, vascular smooth muscle cells, and 
fibroblasts (Herrmann et al., 2000). In addition, Singh et al. was 
demonstrated that vimentin are recently known to bind 
N-acetylglucosamine (GlcNAc) residue, therefore, the cell surfaces of 
vimentin-expression cells could be targeted by using the GlcNAc residue 
as a specific ligand for receptor-mediated gene delivery (Singh et al., 
2014). Vimentin is expressed on the surface of kidney cells or tisssue, in 
particular, glomerular or renal interstitial tissues in normal and/or abnormal 
kidney tissues (Wu et al., 2010). Targeting vimentin receptors can be a 
successful strategy for efficient and specific delivery of genes to the 
kidney because vimentin, which is a type of intermediated filament protein, 
is expressed in developing and adult human kidney (Holthfer et al., 1984). 
Several reports have also described the distribution of vimentin in both 
normal and carcinoma kidney tissues (Skinnider et al., 2005; Gonlusen et 
al., 2001; Beham et al., 1992). Moreover, Scanziani et al. reported that 
vimentin not only expresses in human kidneys (normal or damaged) 
tissues, but also expresses in bovine kidneys with nephritis at interstitial 
regions (Scanziani et al., 1993). In normal kidneys, vimentin can be found 
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in arterioles, interstitial fibroblasts, glomeruli, but not in tubules. 
Interestingly, however, vimentin expression is abundant after tubular injury 
(atrophy, inflammation and/or fibrosis) in experimental models such as 
urethral obstruction (Klahr et al., 2001), kidney aging (Nakatsuji et al., 
1998), ischemic injury (Villanueva et al., 2006; Matos et al., 2007), 
proteinuria (Kikuchi et al., 2000), nephropathy by adriamycin (Shu et al., 
2002), suggesting that overexpression of vimentin can be considered as a 
marker for tubular injury (Vansthertem et al., 2010; Stefanovic et al., 
1996). Moreover, it has been demonstrated that, after kidney 
transplantation, vimentin expression can be assessed as an indicator of 
renal dysfunction (Matos et al., 2007). These evidences strongly suggest 
that vimentin can be a potent receptor used to target the kidneys, 
especially the damaged or obstructive kidney tissues. In addition, vimentin 
can be effectively targeted with high affinity kidney targeting by 
chitobionic acid are prepared. Therefore, it should be possible to use 
surface-expressed vimentin in cells or tissues as targeting sites for gene 
delivery (Kim et al., 2012).  Kim et al. identified that vimentin can be 
effectively targeted with high affinity by chitobionic acid (CBA), prepared 
by dimer of N-acetylglucosamine (GlcNAc) as a specific ligand to the 
vimentin-expressing cells, when conjugated with cationic polymers, 
because we found that the CBA-conjugated polymer showed higher 
transfection efficacy in vimentin expressing cells (the human embryonic 
kidney 293T cells and epithelial HeLa cells) compared to their 
un-conjugated counterparts (Kim et al., 2011; Singh et al., 2014). 
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Mechanistically we also showed the proof-of-concept that these 
CBA-conjugated polymers had no effect when the surface-vimentin was 
knocked-down by RNA interference (Kim et al., 2011). This study 
determined that gene transporter as a kidney targeting ligand was 
successfully synthesized, CBA-PSGT (Fig. 1 and 2). The evidence that 
CBA-PSGT was obtained CBA prepared by dimer of 
N-acetylglucosamine(GlcNAc) and conjugated with the novel gene carrier 
PSGT was investigated.
      (2) UUO model with features of renal fibrosis : The model of UUO 
induces progressive renal fibrosis that is independent of hypertension and 
immune diseases. In addition, UUO model also present several typical 
features of obstructive nephropathy such as tubular injury, interstitial 
macrophages infiltration, and proliferation of renal interstitial fibroblast and 
their transformation into myofibroblasts (Fu et al., 2006). To determine an 
effective delivery of HGF gene with CBA-PSGT specifically to kidney 
showed incredible improvement of UUO symptoms in model rats, UUO 
models were prepared, and confirmed recurrent the healthy condition of 
kidney tissues (Fig. 10). Figure 12. was showed severe tubular dilatation 
and atrophy, and widened interstitial space with a greater number of 
interstitial cells, and infiltrating leukocytes in obstructed kidney with the 
exception of CBA-PSGT/HGF complexes group.  
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       (3) Mechanism of protect of renal fibrosis : To repair and 
regenerate tubular function after acute renal disease, HGF is a key protein 
(Gao et al., 2002; Yang et al., 2002A; Gong et al., 2003; Staunton et al., 
1988) which is not only considered as an endogenous anti-fibrotic factor, 
but also as therapeutic element that blocks renal tissue fibrosis and repair 
dysfunction (Zuo et al., 2009). In addition, HGF prevents accumulation of 
collagen in renal fibrosis (Zuo et al., 2009; Kobayashi et al., 2009). Some 
studies were demonstrated HGF gene or its protein prevents the 
development and progression of renal lesions and dysfuction (Cui et al., 
2013; Yang et al., 2002B). Many factors are known to regulate the 
fibrogenic process after tissue injury, in which transforming growth factor 
(TGF)-β is believed to the principal one that plays a central role. HGF is 
an intrinsic antifibrotic factor that directly antagonizes the profibrotic 
actions of TGF-β (Liu et al. 2004). The data showed that CBA-PSGT 
delivered HGF gene reduced renal injury, decreased the levels of BUN, 
creatinine in serum, and significantly lowered the levels of collagen and 
markedly down-regulated collagen-related proteins such as ICAM-1, 
TIMP-1, and α-SMA levels which are primarily responsible for 
obstructive kidney function. It was previously reported that the level of 
BUN was significantly increased with longer duration of UUO (Tapmeier et 
al., 2008). In another study, June et al. described that both BUN and 
creatinine were significantly elevated in UUO rat model compared to those 
control aniamls (Li et al., 2015), suggesting that BUN and creatinine are 
also good indicators to evaluate renal injury in blood serum of UUO rat 
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model. Proinflammatory cytokines such as IL-6 and IL-1β (Fig. 14) 
could be secreted by inflammatory response and injured tubule cells. 
ICAM-1 (Fig. 17A) is also a critical factor involved recruitment of 
leukocytes to injured tissues. Ureteral obstruction was observed 
inflammatory cells in many forms of chronic kidney diseases, and 
persistent inflammatory response. It contribute to the development of 
tubulointerstitial fibrosis with function impairment. HGF induces the 
degradation of ECM as well as blocks the synthesis of ECM by activating 
of protease such as matrix metalloproteinase (MMPs) (Ojeda et al., 2011; 
Gong et al., 2003). In addition, HGF also influences the balance of MMPs 
secretion and their activators. To maintain ECM deposition, the TIMP-1 
play a key role which inhibits the activation of MMPs (Fu et al., 2006; 
Staunton et al., 1988; Mizno et al., 2000). Therefore, ECM degradation is 
catalyzed by MMPs, which is prevented by the expression of TIMPs 
(Zhang et al., 2006; Sharma et al., 1995). In addition, ICAM-1, which is 
regulated by MMPs in renal injury, also upregulates in several renal 
diseases and relates to the progression of renal lesion (Staunton et al., 
1988; Zhang et al., 2006). In my data, HGF delivered with CBA-PSGT 
group express less ICAM-1 and TIMP-1 than other UUO groups including 
control, naked HGF, and PSGT/HGF. Because imbalance of MMPs and 
TIMP-1 and  ICAM-1, as several inflammatory mediators, is substractes 
of MMPs, resulting to TIMP-1 affect ICAM-1 through MMPs and 
subsequently promote renal fibrosis (Zhang et al., 2006). TIMP-1 could 
enhance renal fibrosis, which was contribute to promoting inflammation 
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though upregulation of ICAM-1. α-SMA was the major source of 
excessive ECM deposition and the prognostic indicator of renal disease 
(Zuo et al., 2009), manifesting a marked activation of the 
metrix-producing myofibroblast cell (Yang et al. 2002B).
        Taken together, these results demonstrated that CBA-PSGT/HGF 
complexes were highly effective to deliver HGF specifically to the kidney 
tissues which showed enhanced recovery of the renal dysfunction, 
impressively by negative regulation of important fibrotic factors such as 
collagen accumulation, ICAM-1, TIMP-1, α-SMA, BUN, and creatinine 
level. In conclusion, it is suggested that CBA-PSGT, might be a novel and 
effective therapeutic to kidney diseases as well as fibrosis. 
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AAV Adeno-associated virus
AKI Acute kidney injury
α-SMA alpha-Smooth muscle actin
BMP7 Bone morphogentic protein 
BUN Blood urea nitrogen
CBA Chitobionic acid
CKD Chronic kidney disease
DN Diabetes nephropathy
ECM Extracellular matrix
GFP Green fluorescence protein 
GlcNAc N-acetylglucosamine
GPC Gel permeation chromatography 
H&E Hematoxylin and eosin
HGF Hepatocyte growth factor
HIF Hypoxia-inducible factor
HSV Herpes simplex virus
HVJ Hemagglutinating virus of Japan







NMR Nuclear magnetic resonance




PSGT Polysorbitol gene transporter
SD Sprague Dawley
STZ Streptozotocin
TEM Transmission electron microscopic
TGF-β Transforming growth factor-β
TIMP-1 Tissue inhibitor of metalloproteinases-1
TNF-α Tumor necrosis factor-α
UUO Unilateral urethral obstruction






        만성신장질환(Chronic kidney disease)은 다양한 원인에 의해서 신장의 
구조 또는 기능적 손상이 일어나 신원(nephron)의 감소와 신기능의 소실이 비가역
적으로 발생하는 신장질환을 말한다. 만성신장질환은 전 세계적으로 다양한 발병 
원인으로 인한 치료법의 부재에 따른 발병률과 사망률이 증가하는 추세이다. 그 중 
신장 섬유증은 만성적이고 점진적인 신장장애의 원인으로 여러 질병으로 존재한다. 
급성 신장 손상으로 인한 비정상적이고 불완전한 복구는 조직의 재생단계를 포함하
고, 이 단계에서 손상된 세포들은 동일한 계열의 세포들에 의해 교체된다. 섬유증성 
단계는 결합 조직이 정상적인 실질조직을 교체하고, 복구는 손상된 부위가 지속되
지 않거나 섬유성 병소가 점진적인 기관장애로 발전한다. 이로써, 신장 섬유증은 만
성적 진행성 신장장애의 원인이다. 이러한 질병을 치료하기 위해 효율적이고, 정확
한 신장질환 치료 방법의 개발을 위해, 많은 시도들이 행해져 왔다. 그 중, 유전자 
전달체를 이용한 유전자 치료방법은 높은 전달효율과 낮은 독성의 이점을 지녀 다
양한 질환 치료에 적용할 수 있다. 또한, 비-바이러스성 유전자 전달체는 쉽게 변
형이 가능하고, 생체 적합한 성질을 지녀 유전자 전달체 치료방법으로 각광받고 있
다. 
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       이번 연구에서는, 항섬유증 인자인 HGF(hepatocyte growth factor)를 도
입한 신장 특이적 키토산접합 폴리소르비톨계 (CBA-PSGT) 유전자 전달체를 이
용하여 신장 섬유증 진행의 방어효과를 확인하였다. 먼저, 신장 특이적 리간드로서 
키토산(Chitonic acid)를 폴리소르비톨계 (PSGT) 전달체에 접합하여 합성하였다. 
키토산은 비멘틴(Vimentin)을 표적화하여 신장으로 효과적으로 전달 할 수 있다. 
더욱이 비멘틴은 정상 신장조직 및 비정상신장조직 뿐만 아니라, 신장의 간질부분
에서 많이 발현된다. 특히나, 비멘틴은 신장위축, 염증, 섬유증을 포함한 신세뇨관의 
장애에서 그 발현량이 과다하게 증가함에 따라 이 유전자는 신세뇨관 장애의 마커
로서 고려될 수 있다. 그러므로 신장세포 또는 신장조직의 표면에 발현하는 비멘틴
은 유전자 전달체의 표적으로서 사용된다. 신장 특이적 유전자 전달체 
(CBA-PSGT)를 합성하여, 유전자 전달체로서의 효율을 평가하였다. 유전자 전달
체는 전달하고자하는 유전자와의 높은 결합유무, 낮은 독성, 높은 효율성으로 목표
하고자 하는 표적에 정확히 작용해야한다. 위 조건에 충족하기 위해 먼저 합성한 
CBA-PSGT와 DNA와의 결합성을 확인하였다. 각 N/P ratio에 따라 DNA와 
CBA-PSGT의 결합력을 확인한 결과, N/P ratio 0.5 이하에서 가장 효과적으로 
나타났다. CBA-PSGT와 콤플렉스를 이룬 DNA는 생체 내에서 많은 효소들의 공
격으로부터 보호되어야 한다. 위 실험에서 CBA-PSGT/DNA 콤플렉스가 DNase로
부터 효과적으로 보호됨을 확인하였다. CBA-PSGT의 세포 내 독성을 확인하기 
위해 신장암세포(293T)와 폐암세포(A549)에서 세포독성실험을 진행하였다. 그 결
과 두 세포에서 CBA-PSGT 전달 그룹에서 90-95%의 세포 생장률을 보여 생체 
내에서 CBA-PSGT가 낮은 독성을 보임을 확인하였다. CBA-PSGT 유전자 전달
체의 높은 신장 타겟 효율성을 확인하기 위해, 293T세포와 A549세포에서의 전달 
효율을 확인한 결과, 신장암세포에서 폐암세포에 비하여 CBA-PSGT 전달효율이 
더 높은 것으로 확인되었다. 마찬가지로 동물 조직에서 각 장기별 CBA-PSGT 전
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달 효율을 확인한 결과 폐, 심장, 간, 비장에 비해 CBA-PSGT 전달이 신장 특이
적으로 나타남을 확인하였다. 따라서, 합성한 CBA-PSGT는 DNA와의 높은 결합
력, 낮은독성 및 신장으로 높은 전달 효율을 가지는 유전자전달체이다. 
        두 번째로, 항섬유증 인자인 HGF가 도입된 CBA-PSGT 전달체를 이용한 
신장 섬유증 방어효과를 평가하기 위한 동물모델로서 일축성 요관 폐색(unilaternal 
ureteral obstruction;UUO) 동물모델을 제작하였다. UUO 동물모델에서 HGF가 
도입된 CBA-PSGT를 전달한 결과 CBA-PSGT/HGF 콤플렉스 그룹에서 유의적
으로 HGF의 발현량이 증가함을 확인하였다. UUO 동물모델은 일반적으로 신장 조
직 손상을 일으키는 질환으로서 주로 세뇨관의 간질조직의 위축과 간질의 섬유화를 
초래한다. 또한, 이로 인한 세뇨관 간질조직 내 염증세포의 침투로 인하여 염증성 
사이토카인이 증가하게 된다. 신장의 조직학적변화를 확인한 결과 항섬유증인자인 
HGF가 도입된 CBA-PSGT 전달그룹에서 신장 조직손상이 덜 일어남을 확인하였
다. 신장 조직의 손상은 지표 중 하나인 혈액 내 BUN과 크레아틴(Creatinine)의 
농도와 염증성 사이토카인인 IL-6와 IL-1β의 발현량이 CBA-PSGT/HGF 콤플
렉스 전달체 그룹에서 유의적으로 감소하였다. 또한, 신장의 섬유화가 진행되면 조
직 내 콜라겐 형성이 증가하게 된다. 콜라겐 I과 II의 발현량 및 신장의 콜라겐축적
의 조직학적 성상을 확인한 결과에서 CBA-PSGT/HGF 콤플렉스 전달체 그룹에서 
콜라겐 형성 및 축적이 억제됨을 확인하였다. 마찬가지로, 신장 섬유화가 진행되면 
콜라겐 형성 및 축적이 이루어지면서 관련 단백질의 발현량이 증가하게 된다. 본 
실험에서 콜라겐 형성과 관련된 단백질인 ICAM-1 과 TIMP-1의 발현량을 확인
하였다. ICAM-1과 TIMP-1은 각각 신장 질환 조직에서 높은 발현량을 보이고, 
세포외 기질(Extracellular matrix;ECM) 형성을 막는 효소인 MMP (matrix 
metalloproteinase) 의 활성을 조절한다. CBA-PSGT/HGF 콤플렉스를 전달시킨 
결과 콜라겐 형성 및 축적 관련 단백질인 ICAM-1과 TIMP-1의 발현량이 감소함
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을 확인하였다. 더나아가, 섬유증 진행과 가장 밀접한 연관있는 단백질 중 하나인 
α-SMA의 발현량 역시 CBA-PSGT/HGF 콤플렉스 전달 그룹에서 억제됨을 확
인하였다. 
         이 연구들의 결과를 요약하면, 신장 특이적 리간드로서 키토산을 접합시
킨 유전자 전달체를 합성하는 데에 성공하였고, 이는 신장질환 및 조직손상에 많이 
발현되는 비멘틴을 표적화하여 신장 특이적 유전자 전달체의 특징을 지니고 있다. 
합성에 성공한 CBA-PSGT 전달체는 유전자 전달체로서 가지는 DNA 와의 결합
력과 효소로부터의 방어력, 낮은 독성 및 특정 표적으로의 높은 전달 효율성을 모
두 지니고 있다. 또한, 신장 섬유증을 완화시키는 항섬유증인자인 HGF를 도입하여 
신장 섬유증을 유발시킨 동물모델에서 섬유증 진행이 방어됨을 보여주었다. 따라서 
이러한 결과들은  CBA-PSGT가 신장질환 치료를 위한 유전자 전달체로서 높은 
가치를 지니고 있다. 
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